BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...
The FDA slammed ExThera with a warning letter for deviating from the regulatory agency’s guidelines by promoting and selling ...
Thermo Fisher Scientific is launching a new test it says can help doctors avoid the “trial-and-error” approach typically used ...
On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. | On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. The first pharma to reach a ...
A new biotech has taken flight as a result of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. | A new biotech has risen from the ashes of Novartis’ ...
Artificial intelligence research biotech Earendil Labs has penned an $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates. | AI research biotech ...
Most immuno-oncology drugs work by altering the tumor microenviro | This webinar covers how recent advances in multiplex ...
Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | A “fairly shocking and certainly ironic twist of fate” is ending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results